Laurus Labs hits 52-week high as strong Q2 results fuel buying

Resumen del corpus

Laurus Labs achieved a new 52-week high following strong earnings in the July-September quarter. The company's performance was driven by significant growth in the CDMO small molecules segment, with net profit nearly tripling year-on-year. This success was supported by a favorable segmental mix and currency benefits, leading to positive analyst ratings and increased investor interest, evidenced by a surge in the stock price.